HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.3%

Neg 0% Neu 90.3% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $25 price target.